BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29205866)

  • 1. Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases.
    Shih YH; Yang Y; Chang KH; Chen YH; Teng CJ
    Int J Rheum Dis; 2018 Jan; 21(1):93-101. PubMed ID: 29205866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History of autoimmune conditions and lymphoma prognosis.
    Kleinstern G; Maurer MJ; Liebow M; Habermann TM; Koff JL; Allmer C; Witzig TE; Nowakowski GS; Micallef IN; Johnston PB; Inwards DJ; Thompson CA; Feldman AL; Link BK; Flowers C; Slager SL; Cerhan JR
    Blood Cancer J; 2018 Aug; 8(8):73. PubMed ID: 30069001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.
    Urbano-Ispizua A; Pavletic SZ; Flowers ME; Klein JP; Zhang MJ; Carreras J; Montoto S; Perales MA; Aljurf MD; Akpek G; Bredeson CN; Costa LJ; Dandoy C; Freytes CO; Fung HC; Gale RP; Gibson J; Hamadani M; Hayashi RJ; Inamoto Y; Inwards DJ; Lazarus HM; Maloney DG; Martino R; Munker R; Nishihori T; Olsson RF; Rizzieri DA; Reshef R; Saad A; Savani BN; Schouten HC; Smith SM; Socié G; Wirk B; Yu LC; Saber W
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1746-53. PubMed ID: 25981509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.
    Jachiet V; Mekinian A; Carrat F; Grignano E; Retbi A; Boffa JJ; Ronco P; Rondeau E; Sellam J; Berenbaum F; Chazouillères O; Capron J; Alamowitch S; Chasset F; Frances C; Coppo P; Fain O;
    Leuk Lymphoma; 2018 Jun; 59(6):1399-1405. PubMed ID: 28972423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
    Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.
    Kleinstern G; Averbuch M; Abu Seir R; Perlman R; Ben Yehuda D; Paltiel O
    Hematol Oncol; 2018 Apr; 36(2):457-462. PubMed ID: 29469175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival.
    Bairey O; Shvidel L; Perry C; Dann EJ; Ruchlemer R; Tadmor T; Goldschmidt N
    Cancer; 2015 Sep; 121(17):2909-16. PubMed ID: 26096161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
    Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
    Cohen JB; Ruppert AS; Heerema NA; Andritsos LA; Jones JA; Porcu P; Baiocchi R; Christian BA; Byrd JC; Flynn J; Penza S; Devine SM; Blum KA
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):278-285.e1. PubMed ID: 25660723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
    Lu Z; Lin M; Downe P; Chong S; Ling S
    Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature.
    Shao YB; Sun XF; He YN; Liu CJ; Liu H
    Med Oncol; 2015 Feb; 32(2):448. PubMed ID: 25572809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study.
    Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Korean J Intern Med; 2016 Sep; 31(5):944-52. PubMed ID: 27384438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.